Your browser doesn't support javascript.
loading
Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.
Toll, Stephanie A; Tran, Hung N; Cotter, Jennifer; Judkins, Alexander R; Tamrazi, Benita; Biegel, Jaclyn A; Dhall, Girish; Robison, Nathan J; Waters, Kaaren; Patel, Palak; Cooper, Robert; Margol, Ashley S.
Afiliación
  • Toll SA; Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Tran HN; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Cotter J; Kaiser Permanente Southern California, Los Angeles, CA, USA.
  • Judkins AR; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Tamrazi B; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Biegel JA; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Dhall G; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Robison NJ; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Waters K; Department of Radiology and Imaging, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Patel P; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Cooper R; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Margol AS; Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Oncotarget ; 10(4): 551-557, 2019 Jan 11.
Article en En | MEDLINE | ID: mdl-30728904